212 results about "Bone resorption" patented technology

The invention provides an application of bifidobacterium animalis subsp. Lactis CP-9 in preparation of a product for promoting bone growth and development or improving bone health. Long-term research and a large number of experiments show that the bifidobacterium animalis subsp. Lactis CP-9 can improve the bone volume fraction, the bone trabecula thickness, the bone density and the bone volume of an organism, and can also effectively improve the growth hormone level and the insulin-like growth factor 1 level, so that bone growth and development are promoted. Meanwhile, the bifidobacterium animalis subsp. Lactis CP-9 can effectively improve the N-terminal propeptide level, osteocalcin level, bone morphogenetic protein level and osteoprotectin level of I-type procollagen in a body, and remarkably reduce the amino-terminal peptide level of the I-type collagen and the ligand level of nuclear factor kappa B receptor activating factor, so that osteoblast differentiation is promoted, osteoclast differentiation is inhibited, and osteoclast differentiation is inhibited. Furthermore, bone formation is promoted, bone resorption is inhibited, bone metabolism is improved, and finally the effect of improving bone health is achieved.

The invention provides a compound with a structure as shown in a formula (I). The compound can be used as a polyphenol organic ligand to be self-assembled with metal ions to form metal polyphenol nanoparticles. The nano-particles have a bone targeting effect, are safe, effective, stable and uniform, can realize whole-body transfer, can be degraded in a bone pathology microenvironment, have regulation and control effects on bone resorption and bone formation, can cooperatively regulate and control bone balance, and have a great application prospect in the field of bone diseases such as osteoporosis. # imgabs0 #

The invention provides a plant lactobacillus TH13, and the preservation number of the plant lactobacillus TH13 is CGMCC (China General Microbiological Culture Collection Center) NO.32112. The plant lactobacillus TH13 provided by the invention can be used for fermenting folium cortex eucommiae and enzymatically hydrolyzed bone meal, and the fermentation product of the plant lactobacillus TH13 has high content of chlorogenic acid, proline, glycine and lysine. The fermentation product can significantly improve the content of alkaline phosphatase (ALP) and osteocalcin (OCN) in mouse serum and reduce the content of tartrate-resistant acid phosphatase (TRACP). Therefore, the fermentation product can significantly improve the bone mineral density of the femur, increase the number of bone trabecula and significantly reduce the separation degree of the bone trabecula, thereby promoting bone formation of a mouse with senile osteoporosis, inhibiting bone resorption and improving senile bone loss and bone microstructure deterioration. The preparation method of the probiotic preparation containing the plant lactobacillus and the probiotic fermentation product is simple, and large-scale production can be realized.

Provided are compositions comprising a HKUOT-S2 protein, at least one peptide according to at least one of SEQ ID NO: 81-97, or a protein comprising an amino acid sequence according to at least one of SEQ ID NO: 81-97. Methods of osteogenesis are provided, including, for example, methods of enhancing bone repair, modulating polarization of macrophages with proinflammatory and anti-inflammatory activity and bone resorption of osteoclasts, and methods of treating inflammatory diseases, spinal cord injury, liver and kidney diseases, cardiovascular diseases, diabetes, post-menopausal syndrome, infertility, or hematopoietic diseases, or enhancing wound healing.

The invention relates to the technical field of oral implantation guidance, and provides a digital false tooth mounting and positioning device based on three-dimensional scanning and a method thereof. The method comprises the following steps: scanning the oral cavity of a patient through an oral cavity scanner to generate a three-dimensional oral cavity digital model; generating a virtual implant of the patient and corresponding initial implantation parameters based on the three-dimensional oral cavity digital model through a SegFormer segmentation network; based on historical operation data, initial implantation parameters, bone density, patient attributes and occlusal force parameters, a long sequence prediction network is adopted to predict the position offset and bone resorption degree of the virtual implant after osseointegration through a segmented attention mechanism and a network memory cache mechanism, and optimal implantation parameters are obtained; and pushing a visual dynamic model containing the candidate positioning strategy to the user based on the optimal implantation parameter, driving an oral cavity model printer to obtain an implantation guide plate model and an oral cavity environment model, assisting the user in verifying the installation effect of the candidate positioning strategy, and improving the accuracy of false tooth installation and positioning.

A method for constructing a microfluidic bone organoid-on-chip can continuously observe the impacts of different external factors on a bone tissue structure based on the “ternary regulation theory” of bone angiogenesis-bone resorption-osteogenesis coupling. The method includes: (1) building a visual three-dimensional cell cultivation platform to continuously observe impacts of different external factors on a ternary regulation theory based on angiogenesis of osteoclast precursors, osteoblasts and osteoclasts, such that a user is allowed to directly observe interactions among various kinds of cells; (2) designing microfluidic channels in a chip to allow a reagent involved to present a concentration gradient distribution in the chip; and (3) adding three bioinks including osteoblasts, osteoclasts and vascular endothelial cells respectively, so as to reflect the three cell components individually, in pairs, and as a whole in the chip. An apparatus for constructing a microfluidic bone organoid-on-chip is further provided.

The invention belongs to the field of medicines, and particularly relates to application of a new target NCSTN for regulating and controlling bone metabolism and an agonist of the new target NCSTN in preparation of a medicine for preventing or treating osteoporosis. The invention aims to provide a new target NCSTN for regulating and controlling bone metabolism and application of the new target NCSTN in promoting osteogenic activity, inhibiting osteoclast activity and treating osteoporosis. According to the invention, the mechanism of the NCSTN agonist for treating osteoporosis is found for the first time, and the NCSTN agonist has the effects of inhibiting osteoclast maturation and differentiation and promoting osteoblast bone formation function. The mechanism is greatly different from the previously reported mechanism of singly inhibiting bone resorption or singly promoting bone formation, and the osteoporosis treatment which simultaneously acts on bone resorption and bone formation can greatly reduce the adverse reaction of the body to the medicine.

The invention relates to the technical field of biological medicines, in particular to rhizoma drynariae extracellular vesicles for treating periodontitis by targeting macrophage ETS2 genes as well as a preparation method and application of the rhizoma drynariae extracellular vesicles. The extracellular vesicles are creatively extracted from the traditional Chinese medicine rhizoma drynariae by combining a differential ultracentrifugation method with a sucrose density gradient centrifugation method, the functions of the extracellular vesicles are studied, and it is found that the extracellular vesicles can effectively slow down alveolar bone resorption in a periodontitis state and reduce periodontal soft tissue inflammation and have a good treatment effect on periodontitis. It is found for the first time that the rhizoma drynariae extracellular vesicles can reduce the inflammatory ability of macrophages in an inflammatory state and can reduce expression of proinflammatory factors TNF-alpha and IL-6. The invention has important scientific research value and clinical significance for further development and application of various traditional Chinese medicine plant extracellular vesicles including rhizoma drynariae extracellular vesicles.

The invention relates to the technical field of medicine, in particular to application of beta-hydroxybutyric acid in preparation of medicine for preventing and / or treating osteoporosis, the osteoporosis comprises postmenopausal osteoporosis and diabetic osteoporosis due to estrogen deficiency, the administration concentration of the beta-hydroxybutyric acid is 150mM, and the administration concentration of the beta-hydroxybutyric acid is 10mM. According to the application of the beta-hydroxybutyric acid in preparing the medicine for inhibiting osteoclast differentiation or osteoclast formation, the beta-hydroxybutyric acid inhibits osteoclast precursor cells from being differentiated into osteoclasts, and the administration concentration of the beta-hydroxybutyric acid is 10 mM; the invention proves that the beta-hydroxybutyric acid improves bone microstructures of OVX mice and db / db mice, inhibits osteoclast differentiation and reduces bone resorption, and provides a new target for prevention and treatment of osteoporosis.

The invention discloses injectable double-drug delivery hydrogel and a preparation method thereof, and belongs to the technical field of biomedical materials. According to the method, two nano microspheres with different charges are respectively prepared by utilizing the characteristics of A-type gelatin and B-type gelatin, a negatively charged medicine EGCG is specifically carried by the positively charged A-type gelatin, and a positively charged medicine SAG is carried by the negatively charged B-type gelatin microsphere; and finally, mixing the two gelatin drug-loaded microspheres into a material taking gelatin and zirconium ions as a substrate to form the composite hydrogel. The hydrogel realizes immune regulation and osteogenesis regulation, also realizes long-acting release of the two drugs, effectively solves the problems of bone resorption, difficulty in healing and the like of host tissues through synergistic regulation of inflammation and mobilization of osteogenesis genes, realizes personalized treatment, and improves the clinical treatment effect and efficiency.

Porous-based bone implants with the integration of Triply Periodic Minimal Surface, TPMS, porous architectures are designed to support the growth and proliferation of bone tissue, bone marrow, and capillaries. This disclosure intends to reduce the adverse effect of conventional implants such as bone resorption over time, which is called the “stress shielding effect”. The “stress shielding effect” is caused by the mismatch between the implant and natural bone stiffness. Triply Periodic Minimal Surface, TPMS, porous architectures exhibit interconnected pore features. The interconnection of the porous network allows the TPMS to have a higher permeability than that of other porous structures, leading to more favorable nutrient transport. In addition, many physical characteristics of the TPMS structures including surface-to-volume ratio, pore size, elastic modulus, and fluid behaviors can be controlled precisely through mathematical manipulation. As a result, TPMS-based implants could be physical features, which are vaned based on different bone regions. In other words, the medical implants may exhibit non-uniform or gradient physical features, which can match the characteristic of trabecular and cortical bones. Therefore, TPMS-based implants could adjust the features to mimic neighboring bone regions. As a result, we can achieve medical implants, which have superior mechanical and biological responses, resulting in optimal cell growth and better medical treatment.

The invention provides a preparation method of a skull for autologous replantation, and relates to the technical field of skull treatment. The method comprises the following steps that the taken-out autologous skull is subjected to ultraviolet radiation and then conveyed into a clean room to be subjected to photographing treatment; sequentially carrying out iodophor soaking, alcohol soaking and normal saline flushing on the skull, and then carrying out surface tissue impurity removal and cleaning on the skull; putting the treated skull into a packaging bag, adding a cryopreservation solution to wrap the skull, and then performing vacuumizing and sealing treatment; and sterilizing and cooling the skull subjected to the sealing treatment, and finally feeding the skull into a bone library for cryopreservation. According to the method, the skull of a patient is taken out after an operation to serve as an autologous bone raw material, so that the skull has bone activity within a certain period of time, finally, the skull is replanted to the skull of the patient, the body burden and conflict psychology of the patient are reduced, the exclusive transportation, treatment and storage modes are adopted, the rejection of the patient is reduced, the risk of bone resorption is reduced, and the bone activity is guaranteed; the replanting rate is increased.

The invention discloses combined lactobacillus salivarius CCFM1398 for regulating and controlling bone homeostasis and relieving bone resorption and a metagen of the combined lactobacillus salivarius CCFM1398, and belongs to the technical field of microorganisms. The combined lactobacillus salivarius CCFM1398 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that expression of protein level and gene level of MC3T3-E1 cell osteoprotegerin (OPG) is improved in vitro; the bone absorption amount of orthodontic bone absorption rat alveolar bone is reduced, the number of alveolar bone osteoclasts is reduced, and the level of rat serum OPG is improved; the secretion of inflammatory factors TNF-alpha, IL-6 and MPO of the orthodontic bone absorption rat is reduced; and the pathological condition of orthodontic bone absorption rat alveolar bone tissue is improved. Therefore, the combined lactobacillus salivarius has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The invention provides a Falcarindiol derivative, preparation thereof and application of the Falcarindiol derivative in preparation of medicines for preventing and / or treating bone diseases. The structural general formula of the Falcarindiol derivative is as shown in formula I in the specification. Experimental results show that the Falcarindiol derivative can significantly inhibit osteoclast differentiation, and is expected to be used for preparing novel drugs for preventing and / or treating osteoporosis, osteoporosis fracture, osteolysis, periprosthetic osteolysis, tumor bone metastasis, inflammatory bone loss, periodontitis inflammatory bone resorption and other bone diseases. # imgabs0 #

The invention relates to application of D-mannose in preparation of products for treating periodontitis. The products comprise medicines, daily necessities and foods. The D-mannose provided by the invention can effectively inhibit the alveolar bone resorption of rats induced by LPS, down-regulate the expression of IL-1beta, IL-6, IL-17, TNF-alpha, G-CSF, GM-CSF, MPO, Ly6G, CD11b, TET2, HK1, HK2 and PFPKB3 in rat gingival tissues treated by the LPS, and up-regulate the expression of IL-10. In addition, the D-mannose can also inhibit the activation of neutrophil stimulated by LPS, down-regulate the expression of IL-1beta, IL-6, IL-17 and TET2, and up-regulate the expression of IL-10.

The invention discloses combined lactobacillus salivarius CCFM1332 with a multi-target regulation effect and application of the combined lactobacillus salivarius CCFM1332 in periodontitis, and belongs to the technical field of microorganisms. The invention discloses a strain of combined lactobacillus salivarius CCFM1332, and the combined lactobacillus salivarius not only has a vaginal immune regulation effect, but also has an effect of relieving periodontitis, which is specifically embodied in that: the combined lactobacillus salivarius can promote vaginal epithelial cells VK2 / E6E7 to secrete antibacterial peptides; the periodontal probing and diagnosing depth of the periodontitis rats can be reduced; the number of pathogenic bacteria in the oral cavity of the periodontitis rat is reduced; the levels of inflammatory factors IL-1beta, IL-6 and IL-17A in serum are reduced; alveolar bone loss of rats suffering from periodontitis is reduced, and the alveolar bone absorption condition of the rats is effectively relieved.

The invention provides a milk protein peptide which takes milk protein as a raw material and has the effects of promoting calcium absorption and improving bone health and application of the milk protein peptide. Specifically, milk protein peptide sequences, including YGGVSL and SQRY, are screened by adopting enzymolysis, sequence identification and molecular docking methods. The milk protein peptide is proved to have high calcium transport promoting capacity in the in-vitro intervention of Caco-2 cells, and the milk protein peptide is proved to have the capacity of promoting osteogenesis and inhibiting bone resorption in the in-vitro intervention of MC3T3-E1 mouse embryo osteoblasts. In animal experiments, by increasing the content of blood calcium and bone calcium, reducing the content of excrement calcium, improving mRNA expression of calcium ion channel protein, calcium binding protein and peptide transporter in intestinal tracts, enhancing the efficiency of calcium entering blood, promoting osteogenesis and inhibiting bone resorption, the milk protein peptide is comprehensively proved to have the capabilities of improving calcium resorption of organisms and improving bone health. The milk protein peptide has both functionality and nutrition, and has a wide application prospect in the aspect of bone health.

The invention discloses a combined lactobacillus salivarius CCFM1397 for improving osteoblast activity and relieving bone resorption and periodontal tissue damage and a metagen thereof, and belongs to the technical field of microorganisms. The lactobacillus salivarius combination CCFM1397 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that: the expression of MC3T3-E1 cell osteoprotegerin (OPG) protein and gene level is improved in vitro; the bone absorption amount of orthodontic bone absorption rat alveolar bone is reduced, the number of alveolar bone osteoclasts is reduced, and the level of rat serum OPG is improved; the secretion of inflammatory factors IL-1beta, IL-6 and TNF-alpha and myeloperoxidase MPO of the orthodontic bone absorption rats is reduced; and the pathological condition of orthodontic bone absorption rat alveolar bone tissue is improved. Therefore, the combined lactobacillus salivarius has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The invention discloses a polylipoic acid-based elastic patch capable of inducing adhesion in a wet environment as well as a preparation method and application of the polylipoic acid-based elastic patch. The polylipoic acid-based elastic adhesion patch can be obtained by simply concentrating and evaporating a mixed solution of lipoic acid and methacrylated gelatin. Due to the introduction of a methacrylated gelatin polymer chain, the layered crystal structure of an original lipoic acid-based polymer is reduced, so that the water sensitivity of the lipoic acid-based polymer is reduced, the release time of lipoic acid active molecules is prolonged, and a small amount of layered crystal structures are reserved in the polylipoic acid-based elastic adhesion patch; therefore, non-adhesion and rigidity are realized in a dry environment. Once exposed to water or body fluid, the hydrophilic polymer backbone of the patch can quickly absorb moisture, the entry of water molecules destroys the layered crystal structure, resulting in softness and adhesion of the patch. In a rat model with ligation of periodontitis, the patch can effectively relieve inflammation and inhibit alveolar bone resorption.

The invention relates to the technical field of medical preparations, and particularly discloses a selenium-based anti-postmenopausal osteoporosis medicine and a preparation method and application thereof.The selenium-based anti-postmenopausal osteoporosis medicine comprises a main active component, a secondary active component and an auxiliary active component, the main active component is a nano-selenium-phytoestrogen compound and is formed by covalent coupling of selenomethionine and soy isoflavone, the particle size of the main active component is 50-200 nm, and the particle size of the auxiliary active component is 100-200 nm; the mass of the selenium element accounts for 5-30% of the mass of the compound; the auxiliary active component is a collagen peptide-calcium chelate and is prepared from marine collagen peptide and calcium citrate through chelation reaction, and the mass ratio of the calcium element to the collagen peptide is (1: 3)-(1: 5); the targeted delivery carrier is folic acid modified chitosan nanoparticles and is used for loading the main active component and the auxiliary active component; the auxiliary materials comprise a disintegrating agent, a lubricating agent and a pH-sensitive enteric coating material; through the synergistic effect of the main active ingredient nano-selenium-phytoestrogen compound and the auxiliary active ingredient collagen peptide-calcium chelate, bone formation can be promoted and bone resorption can be inhibited at the same time, and dual-function treatment is achieved.

The invention relates to the technical field of medical implants, in particular to a 4D printing-based porous Niti alloy bionic bone gradient structure construction method, which comprises the steps of patient bone data acquisition, bionic gradient model design, NiTi powder preparation, 4D printing, thermal treatment activation of memory effect, surface functionalization treatment and mechanical / biological performance test. The method is characterized by comprising the following preparation steps: accurately acquiring bone structure data through CT / MRI, combining Mimics pretreatment and UG / NX modeling, designing aperture and porosity for differentiation of cortical bone (low porosity of 30%-40%) and cancellous bone (high porosity of 50%-70%), simulating typical load working conditions through ANSYS, enabling the elastic modulus (3-15 GPa) and compressive strength (80-200 MPa) to be close to natural bone, and finally obtaining the bone structure data through the CT / MRI, the pore diameter and porosity of the cortical bone (low porosity of 30%-40%) and the porosity of the cancellous bone (high porosity of 50%-70%). According to the design, the elastic modulus difference between the implant and the host bone is remarkably reduced, the bone resorption problem caused by stress shielding is avoided, meanwhile, continuous porosity transition is achieved through the power gradual change technology, and the structural stability under the complex load is improved.

The invention discloses application of a Trim3 gene and / or an expression product thereof in preparation of medicines for treating osteoporosis. The over-expression of the Trim3 can improve the bone mineral density of osteoporosis model mice, inhibit bone resorption, inhibit osteoclast differentiation and inflammatory response in vitro, improve osteoporosis and provide a new target for diagnosis and treatment of osteoporosis.

The invention relates to the technical field of oral cavities, and discloses an alveolar bone resorption degree detection method, device and equipment and a medium, oral cavity image data of a patient is obtained, and tooth jaw segmentation data extraction is performed on the oral cavity image data to obtain tooth jaw segmentation data; performing three-dimensional space morphological feature analysis on tooth segmentation data in the tooth jaw segmentation data to obtain tooth coordinate azimuth information; calculating periodontal measurement surface information according to the tooth coordinate azimuth information; extracting enamel boundary line data and alveolar bone boundary line data in the dental jaw segmentation data; calculating an alveolar bone resorption degree result according to the enamel boundary line data, the alveolar bone boundary line data and the periodontal measurement surface information; the alveolar bone resorption degree result is calculated through the boundary line data and the measurement surface information, and the accuracy of the result is improved while the resorption degree is accurately quantified.

The application discloses a preparation method of a customized porous TMJ prosthesis deposited with europium-doped black phosphorus nanosheets, and comprises the following steps: S1, CBCT is used to shoot medical image data, which is imported into Mimics software to reconstruct a model, the reconstructed model is imported into Geomagic software to simulate bone cutting, and a craniofacial model STL file is obtained; S2, TMJ prosthesis customization design is performed on the craniofacial model STL file; S3, SLM printing technology is adopted to perform 3D printing on the customized TMJ prosthesis model, and a prosthesis entity is obtained; and S4, a polydopamine europium-doped black phosphorus nanosheet surface coating is constructed on the porous region of the prosthesis entity model. The application realizes product customization by adopting computer-aided design and three-dimensional printing technology; the europium-doped black phosphorus nanosheet coating is constructed on the porous region of the prosthesis, the mandibular stump and the buccal region are promoted to grow into bone, the traditional "two-dimensional fixation" is changed into "three-dimensional fixation", and the limitation of screw loosening, falling off and bone resorption is got rid of.

To highly accurately predict effects of a drug administered to a subject.SOLUTION: A prediction system includes an acquisition unit and a prediction unit. The acquisition unit acquires subject information including a medical image showing bones of a subject. The prediction unit outputs drug prediction information regarding effects of drugs acting on at least one of bone formation and bone absorption, using a drug effect prediction model for predicting effects of drugs on the basis of input information including the subject information and drug information on drugs.SELECTED DRAWING: Figure 3

The invention belongs to the technical field of biological medicines, and particularly provides application of Schwann cell exosomes in preparation of medicines for treating osteoporosis. An exosome derived from Schwann cells is prepared, and the inhibition effect of SC-EXO on osteoclasts is proved through TRAP staining, immunofluorescence, bone resorption, RT-qPCR and other experiments on the cell molecule level; meanwhile, the effect of SC-EXO on reduction of bone loss of ovarian extirpation mice is determined through in-vivo experiments. According to the invention, osteoclast formation and bone resorption capability can be inhibited, bone loss of OVX mice can be reduced in vivo, and the compound can be used for treating osteoporosis and other related diseases.

The present disclosure discloses a strain of Lactobacillus fermentum capable of preventing and / or treating periodontitis and an application thereof, belonging to the field of microbiology technology. The present disclosure has screened to obtain a strain of L. fermentum CCFM1139. The L. fermentum CCFM1139 can alleviate periodontitis by inhibiting formation of mixed bacterial biofilms of Porphyromonas gingivalis, Prevotella intermedia and Fusobacterium nucleatum, thereby reducing the amount of biofilm by 52.45%, and can reduce the content of TNF-α from 131.37 pg / mL to 83.31 pg / mL and IL-8 from 147.70 pg / mL to 121.12 pg / mL in a periodontitis cell model, reduce colonization of the P. gingivalis and the F. nucleatum in the oral cavity by 1-2 orders of magnitude, and reduce the amount of the alveolar bone resorption from 1838.0 μm to 805.7 μm.

The invention relates to the technical field of biomedicine, and particularly provides a mouse model capable of being inductively combined with epithelial cell specific ablation and application of the mouse model. The method comprises the following steps: inserting a '3xFLAG-P2A-CreERT2 'functional frame at a fixed point at a termination codon of a mouse Odam gene, so as to obtain an OdamCreERT2 mouse. The expression specificity of the Odam gene in binding epithelium is verified by a mouse obtained by copulating with a ROSA26mT / mG reporter gene mouse; mice obtained by mating with ROSA26DTA cell ablation mice reveal the indispensable function of binding epithelium in maintaining periodontal barrier and preventing bone resorption. The model retains endogenous Odam expression and functions, supports protein dynamic tracing and space-time specific gene manipulation, and is suitable for researching the effect of binding epithelium in periodontal barrier integrity and alveolar bone resorption prevention.

The invention relates to the field of biological medicine, in particular to application of myeloid-derived suppressor cell-derived vesicles in preparation of a medicine for relieving osteoporosis. The bone resorption-resistant drug is entrapped by the myeloid-derived suppressor cell-derived vesicles and is delivered to the myeloid-derived suppressor cells, so that the targeting property of the bone resorption-resistant drug is improved, and bone resorption is inhibited by inhibiting the activity of osteoclasts and the absorption effect of the osteoclasts on bone trabecula; the proportion of abnormal myeloid-derived suppressor cell subgroups in bone marrow can be reduced, formation and activity of osteoclasts are indirectly inhibited, the bone resorption process is further slowed down, and the curative effect of the anti-bone resorption medicine on osteoporosis can be improved.

This invention discloses a histone-derived peptide nanoparticle targeting the degradation of cytoplasmic cGAS, its preparation method, and its applications. The invention is characterized by: dissolving a peptide complex in phosphate buffer, sonicating, allowing it to self-assemble at room temperature to form nanoparticles, and purifying by centrifugation to obtain histone-derived peptide nanoparticles A4@CMA NPs targeting the degradation of cytoplasmic cGAS. These nanoparticles (A4@CMA NPs) can target and bind to cytoplasmic cGAS, mediating its degradation, blocking the activation of the cGAS-STING pathway, effectively reducing periodontal inflammation and alveolar bone resorption, and providing a new strategy for the treatment of periodontitis.